# The Safety and Efficacy of Anti-CD19 CAR-T Cells in Patients With Relapsed/Refractory Autoimmune Diseases

> **NCT06420154** · EARLY_PHASE1 · NOT_YET_RECRUITING · sponsor: **First Affiliated Hospital of Wenzhou Medical University** · enrollment: 9 (estimated)

## Conditions studied

- Systemic Lupus Erythematosus (SLE)
- Sjogren's Syndrome
- Systemic Sclerosis
- Inflammatory Myopathy
- ANCA Associated Vasculitis
- Antiphospholipid Syndrome

## Interventions

- **BIOLOGICAL:** anti-CD19-CAR-T cells

## Key facts

- **NCT ID:** NCT06420154
- **Lead sponsor:** First Affiliated Hospital of Wenzhou Medical University
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2024-05-27
- **Primary completion:** 2027-05-27
- **Final completion:** 2027-05-27
- **Target enrollment:** 9 (ESTIMATED)
- **Last updated:** 2024-05-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06420154

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06420154, "The Safety and Efficacy of Anti-CD19 CAR-T Cells in Patients With Relapsed/Refractory Autoimmune Diseases". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT06420154. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*